Neurology
One Psychedelic Dose Is Now a Phase III Argument
A second Phase III study of single-dose lysergide has reported sustained benefit in generalized anxiety disorder. Psychedelic psychiatry is moving from experimental promise into a regulatory and health-system problem.
Germany Is Paying the Price for Leaving Tardive Dyskinesia Behind
A Rare Childhood Ataxia Gets Real Phase III Evidence
Europe’s next stroke bet: can Factor XIa inhibition change prevention without raising bleeding risk?
A Seizure Diagnosis Should Not Automatically End a Career
Mental Health Patients Need Care, Not Surveillance
Brain-Bleed Care Still Has a Last-Mile Problem
Mental Health Patients Need Care, Not Surveillance
The Brain Can Recover. The System Often Does Not Let It.
CIDP Treatment Moves Beyond the IVIg Default
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
Diseases in Neurology
Explore disease data and country profiles on the IPM Alliance platform.
Explore diseases